理解市场 | 映恩生物-B 高开逾 4% 获纳入恒生综合指数成份股 乳腺癌新药 III 期临床达主要终点
DUALITYBIO-B's stock price opened over 4% higher, rising 4.63% to HKD 380 as of the time of writing, with a transaction volume of HKD 7.506 million. Starting from September 8, 2025, the company's shares will be included in the Hang Seng Composite Index constituents, expanding the investor base. The company also announced that its new breast cancer drug DB-1303/BNT323 has reached its primary endpoint in the Phase III clinical trial and plans to communicate with the drug regulatory authority regarding the application for market approval
According to Zhitong Finance APP, DUALITYBIO-B (09606) opened over 4% higher, and as of the time of writing, it has risen by 4.63%, trading at HKD 380, with a transaction volume of HKD 7.506 million.
On the news front, DUALITYBIO-B announced that starting from September 8, 2025, the company's shares will be included in the Hang Seng Composite Index constituents by Hang Seng Indexes Company Limited and will be added to the list of eligible stocks under the Shanghai-Hong Kong Stock Connect.
The inclusion of shares in the Hang Seng Composite Index and as eligible securities under the Shanghai-Hong Kong Stock Connect represents a high recognition of the company's performance and value by the capital market, allowing qualified investors in mainland China to directly invest in shares listed on the Hong Kong Stock Exchange through the Shanghai Stock Exchange. This inclusion is expected to further expand the company's investor base and is likely to increase the trading liquidity of the shares.
Additionally, it is worth noting that on September 5, DUALITYBIO announced that, following an evaluation by the Independent Data Monitoring Committee (IDMC), the Phase III clinical trial of DB-1303/BNT323 for HER2-positive unresectable or metastatic breast cancer patients who have previously received trastuzumab and taxane treatment has achieved the primary endpoint of progression-free survival (PFS) as assessed by the blinded independent central review (BICR) compared to the control group.
The company plans to communicate with the National Medical Products Administration's Drug Review Center regarding the submission of the Biologics License Application (BLA) for DB-1303/BNT323. DB-1303/BNT323 is a clinical-stage HER2 ADCD candidate drug, currently being evaluated in two ongoing registration clinical trials and another potential global registration study. The company's partner, BioNTech SE, is preparing to submit the drug's marketing authorization application for DB-1303/BNT323 in 2025
